Selenium for Hashimoto's: Evidence & Protocol (2026)

Selenium reduces TPO antibodies in Hashimoto's thyroiditis. This is one of the most replicated findings in integrative thyroid medicine. The 2024 Huwiler meta-analysis (2,358 patients, 29 cohorts) confirmed statistically significant TPO antibody reduction and TSH lowering in patients not on levothyroxine. The standard dose is 200 mcg per day of L-selenomethionine.

Quality-of-life improvement is less consistent across trials, notably absent as the primary endpoint in the CATALYST trial, which is frequently misread as evidence that "selenium doesn't work." It does not mean that. It means selenium didn't improve QoL in LT4-treated patients whose selenium status was never measured. The honest read is more nuanced, and understanding it matters for setting realistic expectations. Discuss all supplementation with your physician before starting.

Why Your Thyroid Needs More Selenium Than Any Other Organ

The thyroid gland is an outlier in human physiology. Per gram of tissue, it concentrates more selenium than any other organ in the body. This is not incidental. The thyroid requires selenium because of how it produces hormones.

Thyroid hormone synthesis is a deliberately oxidative process. The enzyme thyroid peroxidase (TPO) uses hydrogen peroxide (H₂O₂) to iodinate thyroglobulin and couple iodinated residues into T3 and T4. The thyroid generates this hydrogen peroxide on purpose.

The problem: H₂O₂ is highly reactive. Without adequate neutralization, it oxidizes thyroid proteins and damages thyrocytes.

Glutathione Peroxidase and the H₂O₂ Problem

Glutathione peroxidase (GPx), specifically GPx1 and GPx4, neutralizes the hydrogen peroxide generated during hormone synthesis. GPx enzymes are selenoproteins: each molecule requires a selenium atom in its active site.

Without adequate selenium, GPx activity drops. Hydrogen peroxide accumulates. Oxidatively damaged thyroid proteins become autoantigens. TPO antibody production follows.

This is the core mechanistic pathway from selenium deficiency to Hashimoto's autoimmunity: insufficient GPx → H₂O₂ excess → oxidized thyroglobulin and TPO → immune recognition → TPO antibody cascade.

Deiodinases: How Selenium Drives T4-to-T3 Conversion

Beyond H₂O₂ management, selenium is required for all three iodothyronine deiodinase enzymes (DIO1, DIO2, DIO3). These enzymes control the activation and inactivation of thyroid hormones:

• DIO1: Peripherally converts T4 to active T3 (liver, kidney)
• DIO2: Converts T4 to T3 in target tissues including brain, pituitary, and brown adipose tissue
• DIO3: Inactivates T3 to rT3 and T4 to rT2 (prevents local over-stimulation)

All three are selenoproteins. In selenium deficiency, deiodinase activity falls. T4 is not efficiently converted to biologically active T3. The result: normal TSH and T4 on labs, suboptimal T3 at the tissue level, and persistent symptoms.

The "Normal Labs but Still Symptomatic" Patient

A substantial subset of Hashimoto's patients reports fatigue, brain fog, weight gain, and cold intolerance despite "normal" TSH and free T4. DIO2 variation is one explanation. The common DIO2 polymorphism Thr92Ala (rs225014), present in approximately 12–16% of the population, reduces DIO2 activity specifically in brain and pituitary tissue.

Patients with this variant may require higher ambient T4 to achieve adequate local T3 in neurological tissue, explaining persistent symptoms on standard levothyroxine doses. Selenium optimization supports DIO2 function and is a rational first step before adjusting medication.

The Selenium-Deficiency-to-Hashimoto's Pathway

When GPx Drops: The Autoantigen Cascade

The sequence from selenium deficiency to TPO antibody production is well characterized. When selenoprotein expression falls, GPx and thioredoxin reductase (TrxR1) activity decline together.

TrxR1 manages the thioredoxin system, a parallel antioxidant network critical for thyrocyte survival. Both systems fail simultaneously under selenium restriction.

The result in thyroid tissue: accumulated hydrogen peroxide oxidizes thyroglobulin and TPO molecules at their tyrosine residues. These oxidatively modified proteins are processed differently by antigen-presenting cells.

Dendritic cells display the modified epitopes to naïve T cells, triggering a primary immune response against what the immune system now recognizes as non-self. Anti-TPO antibodies are the downstream product.

This explains both why selenium deficiency accelerates Hashimoto's and why selenium repletion, by restoring GPx and TrxR1, can reduce the ongoing antigenic burden and slow antibody production.

The Selenium-Iodine Ratio

The interaction between selenium and iodine is one of the most important and least discussed dynamics in thyroid nutrition. Iodine is required for hormone synthesis and generates hydrogen peroxide as a byproduct. Selenium neutralizes that hydrogen peroxide.

When selenium intake is low and iodine intake is high, the oxidative damage from iodine cannot be adequately buffered.

This explains an epidemiological pattern: populations that introduce iodine supplementation programs into areas of existing selenium deficiency see dramatic increases in Hashimoto's prevalence. The iodine accelerates hormone synthesis and H₂O₂ production; the absent selenium allows that peroxide to damage thyroid tissue unimpeded.

The practical implication: avoid supplemental iodine unless your physician has confirmed you are iodine-deficient. If you do supplement iodine therapeutically, concurrent selenium is mandatory.

The SELENOS Gene: Why Some People Are More Vulnerable

The selenoprotein S gene (SELENOS, formerly known as SEPS1) codes for a selenoprotein involved in the unfolded protein response and endoplasmic reticulum stress regulation in thyroid cells. The rs28665122 variant of SELENOS is a confirmed genetic risk locus for Hashimoto's thyroiditis, discovered in genome-wide association studies. (Hu & Rayman, Thyroid, 2017)

Patients carrying this variant have impaired selenoprotein function in thyroid tissue even when serum selenium is technically "normal." This creates a genetic predisposition in which selenium status interacts with immune risk: adequate selenium is more important, not less, for patients with this variant.

It also explains why some patients do not respond to selenium supplementation as predicted by their serum levels. The functional deficit is at the gene-expression level, not simply the circulating concentration.

What the Clinical Trials Show

The First RCTs: Gartner 2002 and Duntas 2003

The earliest randomized trials established the core result.

Gartner and Gasnier (2002, Journal of Clinical Endocrinology & Metabolism) enrolled 70 patients with Hashimoto's thyroiditis and elevated TPO antibodies. Patients received 200 mcg sodium selenite per day or placebo for three months, followed by a crossover phase. After three months, TPO antibodies fell 40% in the selenium group versus 0% in placebo.

The crossover phase added a critical finding: when patients stopped selenium, TPO antibodies rebounded. This established that selenium's antibody-lowering effect requires continuous supplementation.

Duntas et al. (2003) used L-selenomethionine rather than inorganic selenite, 200 mcg per day for six months, in 65 Hashimoto's patients. TPO antibodies fell 46% at 3 months and 55.5% at 6 months versus placebo. This demonstrated both greater magnitude and a continued response with sustained supplementation, arguing against a plateau effect at 3 months.

The CATALYST Trial: What It Found and What It Did NOT Test

The CATALYST trial (Winther et al. 2019, The Lancet Diabetes & Endocrinology) is the largest selenium RCT in Hashimoto's to date: 472 patients, 200 mcg selenium-enriched yeast versus placebo, 12 months. It is also the most misread trial in the thyroid supplement literature.

Primary endpoint: Quality-of-life score (ThyPRO). Result: no statistically significant difference at 12 months.

What most articles report: "The CATALYST trial showed selenium doesn't work."

What CATALYST actually showed:

1. The primary endpoint was QoL (not antibody reduction). Selenium was not tested for what it mechanistically does.
2. TPO antibodies did fall significantly in the selenium group at 6 months.
3. All 472 enrolled patients were on levothyroxine (pharmacologically euthyroid). The QoL deficit in LT4-treated Hashimoto's patients is multifactorial, with many causes that selenium cannot address.
4. Baseline serum selenium was not measured in CATALYST participants. Some or many may have been selenium-sufficient already, in which case supplementation adds marginal benefit.
5. Subgroup analysis in the Huwiler 2024 meta-analysis (which includes CATALYST data) found significant TSH reduction in the non-LT4 subgroup, the patients most likely to benefit from selenium's thyroid-regulatory effects.

The accurate interpretation: selenium did not improve QoL in LT4-treated, selenium-unmeasured patients at 12 months. It does reduce TPO antibodies. These are different claims.

Huwiler 2024: The Definitive Meta-Analysis

Huwiler et al. (2024, Thyroid, PMID 38243784) is the most comprehensive synthesis of the evidence: 29 cohorts, 2,358 participants, covering multiple RCTs and intervention forms. Key findings:

• TPO antibodies: SMD –0.96 (95% CI –1.36 to –0.56): significant, large effect size
• TSH: SMD –0.21 (95% CI –0.43 to –0.02) in the non-LT4 subgroup: significant
• MDA (malondialdehyde, oxidative stress marker): Consistently reduced across cohorts
• Selenomethionine subgroup: Outperformed inorganic selenium forms
• Independent of baseline TPOAb level: Effect seen across antibody tiers

This meta-analysis includes the CATALYST trial and still shows significant TPO antibody reduction. CATALYST alone is not the evidence. It is one data point in a much larger body.

The Immune Mechanism: Treg Cells, Not Just Antioxidants

Beyond the antioxidant mechanism, selenium influences the adaptive immune system directly. Hu et al. (2021, PMID 33650299) conducted a randomized trial in approximately 120 Hashimoto's patients comparing selenomethionine 200 mcg/day to placebo for 6 months. Beyond TPO antibody reduction, they measured immune cell populations.

Selenium supplementation significantly increased FOXP3+ regulatory T cells (Tregs), the immune cells responsible for maintaining self-tolerance and suppressing autoreactive lymphocytes. Simultaneously, pro-inflammatory cytokines IL-2, IL-6, and IL-17 fell in the selenium group. IFN-γ and TNF-α decreased.

This is mechanistically important: selenium is not simply a passive antioxidant that mops up hydrogen peroxide. It actively modulates the T-cell balance that determines whether the autoimmune attack continues or is suppressed.

Treg upregulation is the same mechanism targeted by low-dose naltrexone and vitamin D at the immune level. This reinforces why a multi-pronged protocol outperforms any single intervention.

Selenium + Myo-Inositol: Why the Combination Outperforms Selenium Alone

Myo-inositol is a naturally occurring sugar alcohol that functions as a second messenger in phosphatidylinositol (PI) signaling. In thyroid cells, the PI cascade is the primary intracellular pathway downstream of TSH receptor activation. It mediates iodine uptake, thyroid peroxidase activity, and thyroid hormone secretion.

When myo-inositol is depleted in thyroid follicular cells (which occurs in Hashimoto's through mechanisms not yet fully elucidated), TSH receptor sensitivity falls. The pituitary compensates by increasing TSH secretion. Subclinical hypothyroidism (TSH elevated but not yet requiring levothyroxine) is one of the earliest and most common presentations of this dysregulation.

Myo-inositol repletion restores PI signaling, improves TSH receptor sensitivity, and may upregulate selenoprotein expression through shared downstream signaling pathways, creating a mechanistically coherent basis for synergy with selenium.

The Nordio 2017 Data

The Italian RCT by Nordio and Basciani (2017, PMID 28724185) enrolled 168 Hashimoto's patients with subclinical hypothyroidism (TSH 3–6 mIU/L) and randomized them to three groups: myo-inositol 600 mg combined with selenomethionine 83 mcg daily, selenium alone, or controls for six months.

Results in the combination group:

• TSH fell 31–38% (versus modest change in selenium monotherapy)
• Thyroglobulin antibodies (TgAb) fell 51%
• Quality of life on the MSQ scale improved 49% (from 4.67 to 2.37)
• No levothyroxine was started in the combination group during the trial period

The selenium dose used (83 mcg) is notably lower than the 200 mcg used in most monotherapy trials. This suggests myo-inositol potentiates selenium's effect, allowing a lower selenium dose to achieve superior outcomes, which is relevant for patients concerned about long-term selenium accumulation.

Zuhair 2024 Confirmation at Population Scale

The 2024 meta-analysis by Zuhair et al. (PMID 39650307) directly compared selenium monotherapy to selenium plus myo-inositol combination across multiple RCTs. The combination produced 115% greater TSH reduction than selenium alone. TgAb fell 51% in combination group patients versus less consistent reduction with selenium alone.

Who should consider the combination:

• TSH in the 2.5–6.0 mIU/L subclinical hypothyroid range
• TgAb positive (not just TPOAb positive): the Nordio trial specifically targeted TgAb-positive patients
• Not yet on levothyroxine, or looking to optimize before initiating medication
• Seeking QoL improvement alongside antibody reduction (Nordio 2017 showed QoL benefit that pure selenium trials often missed)

For the full supplement context and interactions with other interventions, see the complete evidence-ranked supplements guide for Hashimoto's. For a deep dive on myo-inositol's mechanism, dosing, and how it works alongside selenium, see the myo-inositol for Hashimoto's evidence guide. For a broader view of how selenium and other supplements are graded across all autoimmune conditions, see the complete autoimmune supplement guide.

Selenomethionine vs. Sodium Selenite vs. Brazil Nuts

The form of selenium matters. Mechanistic differences in absorption, metabolism, and tissue distribution produce meaningfully different clinical results.

The Brazil Nut Problem

Brazil nuts are frequently recommended as a natural selenium source. The recommendation is well-intentioned but imprecise in a way that matters clinically.

Selenium content in Brazil nuts depends almost entirely on the selenium concentration in the soil where the tree grew. Studies measuring selenium in commercially available Brazil nuts have found ranges from as low as 11% of the daily RDA per nut to 288% per nut.

Two Brazil nuts from different sources, both looking identical on a shelf, might deliver 10 mcg or 550 mcg of selenium. With a tolerable upper limit of 400 mcg/day, the latter puts you above the safe threshold without knowing it.

If you eat 2–3 Brazil nuts from a reliable source (typically Amazonian origin) a few times per week as a dietary supplement alongside an otherwise selenium-adequate diet, this is reasonable. For the consistent 200 mcg/day dose shown effective in RCTs, L-selenomethionine capsules are the reliable choice.

Functional medicine consensus: L-selenomethionine, 200 mcg/day for Hashimoto's monotherapy. 83 mcg/day when combined with myo-inositol 600 mg/day.

How Much Selenium to Take

Standard Dose

200 mcg/day L-selenomethionine is the dose used in every major positive RCT for Hashimoto's. This is below the tolerable upper intake level (UL) of 400 mcg/day and has been used safely in clinical trials for up to 12 months without documented selenosis.

Pregnancy Dose

Lower doses are appropriate during pregnancy. The SERENA trial used 83 mcg/day and observed reduction in postpartum thyroiditis incidence. The 200 mcg/day dose used in adult Hashimoto's trials has not been systematically studied in pregnancy.

If you are pregnant or planning to become pregnant, discuss selenium dose with your obstetrician. The standard prenatal RDA is 60–70 mcg/day.

Selenium + Myo-Inositol Protocol

83 mcg/day selenomethionine combined with 600 mg/day myo-inositol (Nordio 2017 protocol). Lower selenium dose is used because myo-inositol potentiates the effect. Note that some clinical accounts use the combination with 200 mcg selenium. Discuss with your physician which approach is appropriate based on your baseline TPOAb and TSH.

Testing Before Supplementing

Testing is not strictly required before starting 200 mcg/day, as this dose is below the UL for most adults. However, testing is recommended in two situations:

1. High dietary selenium intake: If you regularly eat large amounts of Brazil nuts, organ meats, and seafood, your baseline may already be adequate. Testing prevents unnecessary supplementation.
2. Suspected response failure: If you have been supplementing and antibodies have not changed at 6 months, a serum selenium test reveals whether tissue levels are actually being achieved.

Optimal serum selenium range: 100–125 mcg/L. Below 80 mcg/L indicates deficiency. Above 150 mcg/L warrants dose reassessment. For a full overview of optimal lab targets in Hashimoto's, see the Hashimoto's lab targets guide. Plasma selenoprotein P (SELENOP) is a more sensitive functional marker than serum selenium. It reflects hepatic selenoprotein synthesis and is a better indicator of body selenium status.

Duration of Supplementation

Based on the Gartner 2002 crossover data showing antibody rebound after cessation, indefinite supplementation is indicated for patients with continued Hashimoto's disease activity. This should be framed as a long-term intervention, not a course to run for 6 months and stop. Retest TPO antibodies and serum selenium annually to confirm continued response and safety.

Who Benefits Most and Who May Not

Selenium-Deficient Patients, Pre-Levothyroxine, High TPOAb

This is the group with the strongest evidence for benefit. Patients who:

• Live in selenium-depleted soil regions (UK, Ireland, Finland, parts of Eastern Europe, Pacific Northwest US)
• Have not yet started levothyroxine (the Huwiler meta-analysis showed the strongest TSH reduction in this subgroup)
• Have highly elevated TPOAb (>500 IU/mL): more room for antibody reduction
• Have subclinical hypothyroidism with TSH in the 2.5–6 range: combination protocol may normalize TSH

For these patients, the evidence for meaningful benefit is consistent across multiple trials.

On Levothyroxine: The CATALYST Context

Patients already on levothyroxine (pharmacologically euthyroid) still benefit from selenium, but the primary outcome is TPO antibody reduction rather than TSH normalization. Since TSH is already controlled by medication, the driver for selenium use is reducing the ongoing autoimmune attack and its long-term consequences for glandular tissue.

CATALYST showed TPO antibody reduction even in this population. The failure to improve QoL at 12 months likely reflects that QoL in LT4-treated Hashimoto's patients is driven by factors selenium cannot address (levothyroxine dose optimization, T3 levels, non-thyroid comorbidities).

Antibody reduction is still a meaningful goal: lower TPO antibodies correlate with less progressive glandular damage and may reduce need for dose escalation over time.

Selenium-Replete Patients: When Supplementation May Not Help

If your diet provides consistent selenium (you eat seafood 3+ times per week, Brazil nuts regularly, and significant organ meats), and your serum selenium tests above 100 mcg/L, additional supplementation adds marginal benefit and carries a theoretical risk of chronic excess.

The SELECT trial (Selenium and Vitamin E Cancer Prevention Trial) tested 200 mcg/day selenium in over 35,000 men followed for up to 12 years. It found no cancer prevention benefit and a statistically significant increase in type 2 diabetes risk. Critically, this was in men who were selenium-sufficient at baseline (mean serum selenium ~135 mcg/L at enrollment).

This is the context for the selenium-diabetes signal: supplementation above adequacy in selenium-replete individuals. It does not apply to the selenium-deficient Hashimoto's patient.

Safety and Drug Interactions

Selenosis: What It Looks Like

Selenium toxicity (selenosis) follows a recognizable progression at chronic intakes above 400–900 mcg/day:

1. Early: Garlic-like breath odor (from dimethyl selenide) and a metallic taste
2. Intermediate: Nail brittleness, white transverse lines on nails, hair loss (diffuse, telogen effluvium pattern)
3. Severe: Peripheral neuropathy, fatigue, GI distress, irritability
4. Rare/acute high-dose: Respiratory distress (industrial exposure levels)

At 200 mcg/day, selenosis is not seen in clinical trials. Risk begins when dietary selenium plus supplemental selenium approaches the tolerable upper limit of 400 mcg/day. In regions with selenium-rich soil (parts of South Dakota, Nebraska, Wyoming, and Japan), dietary intake alone may reach 100–200 mcg/day, making supplementation less necessary and toxicity more plausible.

If you develop unexplained hair loss or nail changes while taking selenium, reduce the dose to 100 mcg/day and retest serum selenium before stopping entirely.

Drug Interactions

Who Must Test Before Supplementing

The following patients should test serum selenium before starting 200 mcg/day:

• Dietary selenium intake is known to be high (Japan, volcanic soil regions, heavy Brazil nut consumption)
• Existing selenium supplementation already in place at any dose
• Chronic kidney disease (impaired selenium excretion)
• Active chemotherapy or planned cancer treatment

Advanced Angles

Post-COVID Thyroiditis: A Mechanistic Connection

SARS-CoV-2 appears to interact with the selenium system in thyroid tissue in a specific and damaging way. The SARS-CoV-2 main protease (Mpro, also called 3CLpro) cleaves host proteins with a cysteine at the active site. Both GPx1 and TrxR1 have cysteine residues near their active sites that are susceptible to Mpro-mediated cleavage.

This mechanism, direct selenoprotein disruption by SARS-CoV-2 protease, provides a molecular explanation for the elevated rates of autoimmune thyroid disease observed in COVID-19 survivors. A 2023 prospective study found autoimmune thyroid disease prevalence doubled in COVID-19 survivors compared to matched controls. In post-COVID thyroiditis, the case for selenium repletion is particularly strong: the infection has likely depleted or impaired the selenoprotein system that normally protects the thyroid from oxidative autoantigen generation.

If you developed thyroid antibodies or worsening thyroid function after a COVID-19 infection, serum selenium testing and supplementation in the deficient range is mechanistically well-justified.

Regional Soil Depletion: Geography Matters

Selenium status is geographically determined more than by any dietary choice. Key risk regions for selenium deficiency:

• United Kingdom and Ireland: Soils are consistently low in selenium. Average dietary intake is 30–40 mcg/day, well below the 55 mcg RDA and far below the 100–200 mcg range associated with clinical benefit.
• Finland: Historically selenium-deficient. Finland added selenium to agricultural fertilizers in the 1980s and saw declines in thyroid cancer incidence subsequently.
• Much of Europe and New Zealand: Moderate to severe selenium depletion in many regions
• Pacific Northwest, US: Lower than Great Plains; significant regional variation
• High-risk areas: Japan (high dietary selenium, caution with supplementation) and parts of South Dakota, Nebraska (selenium-rich soil: lower supplementation need)

If you live in a historically selenium-deficient region, baseline deficiency should be assumed unless tested otherwise. This population represents the "ideal responder" profile for selenium supplementation in Hashimoto's.

Where Selenium Fits in a Complete Hashimoto's Protocol

Selenium does not operate in isolation. In the full Hashimoto's protocol framework, it sits in Tier 2 (Condition-Specific Supplements), alongside vitamin D3, the selenium-myo-inositol combination, zinc, and ferritin repletion.

Tier 1 foundation interventions (the AIP diet, gut healing, and omega-3 fatty acids) create the environment in which selenium is most effective. A selenium supplement cannot compensate for severe intestinal dysbiosis that perpetuates systemic inflammation, or for the antigenic burden created by unaddressed gluten sensitivity.

Tier 3 interventions (LDN, fasting mimicking diet) work through different mechanisms (opioid receptor modulation, autophagy, and immune regeneration) and are additive to selenium rather than substitutable.

For the complete protocol with all tiers and condition-specific decision criteria, see the Hashimoto's natural treatment protocol guide.

Frequently Asked Questions

Does selenium lower TPO antibodies?

Yes, in most patients who supplement. The Huwiler 2024 meta-analysis pooled 29 cohorts and 2,358 participants and found a statistically significant TPO antibody reduction (SMD –0.96). Earlier trials by Gartner 2002 and Duntas 2003 documented 40–55% reductions at 200 mcg/day. The effect is most pronounced in patients who are selenium-deficient at baseline and not yet on levothyroxine. In LT4-treated patients, the CATALYST trial confirmed TPO antibody reduction at 6 months even in pharmacologically euthyroid patients.

How long does it take for selenium to work for Hashimoto's?

Most trials showing significant TPO antibody reduction used supplementation periods of 3 to 6 months. Gartner 2002 showed a 40% reduction at 3 months. Duntas 2003 showed 46% reduction at 3 months and 55.5% at 6 months. Retest TPO antibodies no earlier than 3 months after starting. For TSH normalization with the myo-inositol combination, meaningful changes were observed at 6 months in the Nordio trial.

What form of selenium is best for Hashimoto's?

L-selenomethionine is the preferred form based on clinical trial data and bioavailability studies. It is an organic, amino-acid-bound form with approximately 90% bioavailability, superior to inorganic sodium selenite (~50–70%). Selenium-enriched yeast (used in CATALYST) is also effective. Brazil nuts are a natural source but have highly variable selenium content, making consistent therapeutic dosing impossible.

Can I get enough selenium from Brazil nuts?

Brazil nuts contain selenium, but the amount varies from 11% to 288% of the RDA per nut depending on soil origin. For therapeutic antibody reduction, consistent dosing at 200 mcg/day is required. Supplemental L-selenomethionine is the reliable approach. If you enjoy Brazil nuts as food, 2–3 from Amazonian origin as a supplement to an otherwise selenium-adequate diet is reasonable. This should not substitute for consistent therapeutic dosing if your TPO antibodies are elevated.

Is selenium safe to take with levothyroxine?

Yes, with low interaction risk. No significant pharmacokinetic interaction between selenomethionine and levothyroxine has been documented in clinical trials. The CATALYST trial enrolled 472 patients on levothyroxine and used 200 mcg/day selenium-enriched yeast for 12 months without safety concerns. As a general precaution, separate selenium supplementation from levothyroxine by at least 2–4 hours.

Does selenium work if my labs are already normal?

The evidence is less consistent for selenium-replete patients. If your dietary selenium intake is already adequate (serum selenium above 100 mcg/L), additional supplementation adds marginal benefit. The SELECT trial found a type 2 diabetes signal in selenium-sufficient men supplemented at 200 mcg/day over years. This is the context in which caution is warranted. Test first if you eat significant amounts of Brazil nuts, organ meats, or seafood regularly.

What happens if I stop taking selenium?

Gartner 2002 included a crossover phase where patients who stopped selenium saw TPO antibodies rebound significantly within 6 months. This suggests the effect requires continuous supplementation. The mechanism is consistent: GPx and TrxR1 activity declines when selenium intake drops, restoring the oxidative environment that promotes autoantigen generation and TPO antibody production. Frame selenium as an ongoing intervention rather than a course.

Where to Start

If you have Hashimoto's thyroiditis with elevated TPO antibodies and have not yet systematically addressed selenium, the evidence supports starting here:

1. Test serum selenium if you live in a selenium-adequate region or eat a high-seafood diet (optional but useful for baseline)
2. Start selenomethionine 200 mcg/day (or 83 mcg/day if combining with myo-inositol 600 mg/day)
3. Separate from levothyroxine by at least 2–4 hours if you take it
4. Retest TPO antibodies at 3 and 6 months: do not retest earlier
5. Continue indefinitely if antibodies are falling; reassess annually

To find out where selenium fits within your specific condition profile, lab values, and medication status, take the free AutoimmuneFinder quiz. The protocol engine maps your answers to a tiered, evidence-graded protocol with dosing guidance for each recommendation.

This article is for educational purposes only and does not constitute medical advice. Hashimoto's thyroiditis is a medical condition requiring professional management. Selenium supplementation, while generally safe at the doses discussed, should be reviewed with your physician or endocrinologist, particularly if you take levothyroxine, warfarin, or other prescription medications, or if you are pregnant. Dosing recommendations reflect general ranges from published clinical trials. AutoimmuneFinder does not diagnose, treat, or prescribe.